Clinical Trial Update: A Study to Assess the Efficacy and Safety of Golimumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis [Phase 3]

View source ↗

Summary

A Phase 3 pediatric trial evaluating golimumab for moderately to severely active ulcerative colitis has results posted; the study is currently not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ulcerative Colitis

Drugs mentioned

• Simponi (golimumab)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Colitis, Ulcerative | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2025-11-14